ScreenPoint Medical

by ScreenPoint Medical  · Based in Netherlands → — We are the Breast AI Company. We are bringing AI to the fight against breast cancer with leading clinical evidence and the latest deep learning technology.
breast-imaging Oncology Radiology

Regulatory Status Disclosed

Overview

ScreenPoint Medical is a leading innovator in AI-driven solutions for breast cancer detection and diagnosis. Their flagship product, Transpara, is an enterprise-grade AI tool designed to assist radiologists in interpreting mammograms and digital breast tomosynthesis (DBT) images. By leveraging advanced deep learning algorithms, Transpara aims to improve the accuracy and efficiency of breast cancer screening programs.

Transpara integrates seamlessly into existing radiology workflows, working alongside radiologists to provide a ‘second read’ or to prioritize studies based on AI-identified suspicious areas. This can help reduce reading times, decrease recall rates, and potentially improve the early detection of breast cancer, ultimately benefiting patient outcomes.

The platform is built with a strong emphasis on clinical validation and regulatory compliance, holding multiple regulatory clearances globally. ScreenPoint Medical collaborates with leading healthcare providers and PACS vendors to ensure secure and effective deployment within diverse clinical environments, including integration with platforms like Microsoft for Healthcare.

Physicians evaluating Transpara will find a tool designed to augment their expertise, providing objective and consistent analysis of breast imaging studies. Its capabilities extend to both 2D mammography and 3D DBT, offering comprehensive support for modern breast imaging practices. The company offers demonstrations to showcase the tool’s capabilities and discuss integration possibilities.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • AI-powered breast cancer detection
  • 2D mammography analysis
  • 3D digital breast tomosynthesis (DBT) analysis
  • Second-read assistance for radiologists
  • Prioritization of suspicious cases
  • Integration with PACS systems
  • Enterprise-grade deployment
  • Regulatory clearances (FDA, CE Mark, Health Canada, TGA)

Use Cases

  • Breast cancer screening programs
  • Radiologist workflow optimization
  • Improving early detection rates
  • Reducing recall rates
  • Standardizing mammography interpretation
  • Training and quality assurance in breast imaging

What Physicians Need to Know

Evidence Base
ScreenPoint Medical's Transpara boasts an industry-leading body of clinical evidence, with over 55 peer-reviewed publications as of late 2025, and dozens of studies presented at major radiology conferences. It is the only breast cancer detection AI solution validated by randomized controlled trials (RCTs), including the MASAI study in Sweden, the PRISM trial in the USA, and the AIMS trial in Norway. The MASAI trial demonstrated a 29% increase in cancer detection and a 44% reduction in screen-reading workload compared to standard double reading, without increasing false positives. Transpara's performance has been evaluated in over 50 peer-reviewed studies and numerous conference presentations, with all data publicly available.
Clinical Validation Studies
Transpara has been rigorously validated in several large-scale studies. The MASAI study, a randomized controlled trial involving over 100,000 women in Sweden, showed a 29% increase in cancer detection and a 44% reduction in workload. A Dutch study of over 40,000 FFDM exams found AI detection comparable to double human reading. In a US study, Transpara flagged 76% of 3D mammograms initially read as normal but later linked to interval breast cancer, and 90% of missed reading error cases. The PRISM trial, a $16 million randomized controlled trial in the US, is currently evaluating Transpara's impact on early breast cancer detection, mammography accuracy, and patient callbacks. The AIMS trial in Norway is also investigating Transpara's latest algorithm. Studies have also shown Transpara's cost-effectiveness, with potential savings of u20ac59,320 per 1,000 women screened and an increase of 10.8 quality-adjusted life years.
Alert Fatigue Management
Transpara aims to reduce radiologist workload and cognitive overload, which are significant contributors to burnout and potential alert fatigue in breast imaging. By categorizing exams into 'Low,' 'Intermediate,' and 'Elevated' risk, and leaving 'Low Risk' cases unmarked, Transpara allows for more efficient review of approximately 70% of screening studies. Low-risk studies boast a 99.97% negative predictive value, increasing confidence in expedited review. This approach helps radiologists focus on higher-risk cases, potentially mitigating the effects of alert fatigue by reducing the number of alerts for benign findings.
Override Rate Data
While specific override rate data for Transpara is not explicitly detailed, the system is designed to provide decision support and act as a 'second pair of eyes,' rather than replacing the physician's judgment. The concurrent use indication implies that users decide how to integrate Transpara into their reading process. The goal is to enhance detection and reduce workload, suggesting that the AI's findings are intended to be valuable and trusted, thereby potentially reducing the need for overrides due to irrelevant alerts.
Differential Diagnosis Support
Transpara Detection identifies soft-tissue lesions and calcifications, assigning a score to both regions and the exam as a whole, representing the likelihood of malignancies. It categorizes areas of suspicion using a 98-point scale and assigns an overall exam category (Elevated, Intermediate, or Low) based on the highest region risk. This risk stratification and highlighting of suspicious areas provide crucial information to support radiologists in their differential diagnosis process.
Guideline Update Frequency
ScreenPoint Medical is committed to continuously evolving its Breast AI with innovative new products and enhanced algorithms. The company consistently strives to build products grounded in real-world problems and substantiated by rigorous scientific scrutiny. This implies ongoing development and updates to ensure the AI aligns with the latest clinical understanding and guidelines. For example, Transpara 2.1 offers notable performance increases in sensitivity compared to previous versions.
Clinical Workflow Integration
Transpara is designed for seamless and adaptable integration into existing radiology workflows. It can be used before, during, or after visual interpretation of an exam. It is integrated with platforms like Aidoc's aiOSu2122, Microsoft's Precision Imaging Network, and Ferrum Health's Model Hub, providing a unified interface for AI results and streamlining deployment. The system supports screening and diagnostic evaluations for both 2D mammograms and tomosynthesis (3D mammograms). It also integrates with reporting systems like Ikonopedia, allowing radiologists to view AI-powered insights alongside patient records and prioritize urgent cases. Transpara can function as decision support, an independent second reader, or a tool to optimize workflow, including potentially replacing a second reader or acting as a third reader in double-reading environments.
Physician Tip

Leverage Transpara's risk stratification to prioritize your workload, focusing on 'Elevated' and 'Intermediate' risk cases. Trust the high negative predictive value (99.97%) of 'Low Risk' cases to expedite their review, thereby improving efficiency and reducing cognitive load. Integrate Transpara's findings, including region-based scores and overall exam scores, into your diagnostic process for a 'second pair of eyes' to enhance confidence and detection. Utilize the temporal comparison feature to track findings across prior mammograms for more effective longitudinal comparisons. Remember that Transpara is a decision support tool, and your clinical judgment remains central to all patient management decisions.

Transpara is designed for broad compatibility and integrates seamlessly with various clinical ecosystems. It is available through platforms like Aidoc's aiOSu2122, Microsoft's Precision Imaging Network, and Ferrum Health's Model Hub, simplifying deployment and providing a unified interface for AI results. It also integrates with reporting systems such as Ikonopedia. The solution is vendor-agnostic, working with any acquisition gantry and readable in any preferred reading environment, ensuring flexibility within existing infrastructure.

Details

Category Clinical Decision Support & Reference, Oncology AI, Radiology & Imaging AI
Pricing Unknown
DeploymentCloud-enabled access through Precision Imaging Network (Microsoft for Healthcare), integrates into PACS and reading workflows via medical-imaging (DICOM) pipelines, on-premise installations.
API Available Yes
Compliance
BAA AvailableUnknown
HIPAA CompliantUnknown
FDA Status Cleared AI-estimated
GDPR Yes AI-estimated
Integrations
EHR Not specified
Specialties Breast Imaging, Oncology, Radiology

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate ScreenPoint Medical

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money
No press coverage or publications on file yet. Know of some? Suggest an edit →

Videos

Product demos, reviews, and walkthroughs for ScreenPoint Medical.

View all on YouTube

Frequently Asked Questions

ScreenPoint Medical's Transpara AI is designed to be used concurrently by physicians interpreting 2D and 3D mammography exams. It functions as a decision support tool, helping radiologists identify suspicious regions, categorize areas of suspicion with a 98-point scale, and assign an Exam Category (Elevated, Intermediate, or Low) based on the highest Region Risk. This helps radiologists read exams faster and with more confidence, potentially increasing cancer detection and reducing workload.
Transpara has received FDA clearance (K241831 and K232096) and CE (0344) certification, and its algorithms are cleared in 40 countries globally. It is supported by over 50 peer-reviewed studies and has been deployed on a national and global scale, with large-scale studies from Denmark, Norway, and Spain attesting to its real-world impact. The MASAI randomized controlled trial, the first RCT in this field, demonstrated that Transpara Detection improves cancer detection by 29% while reducing reading workload by 44%.
Transpara is intended as an adjunct tool and not a replacement for a physician's own review of a mammogram; patient management decisions should not be made solely based on its analysis. While it aims to improve workflow and confidence, physicians should be aware that discussions of autonomous or 'rule-out' applications are currently investigational and not FDA-cleared or covered by the current CE certificate.
While the specific comparison data to all alternatives is not provided, ScreenPoint Medical asserts that Transpara has more peer-reviewed publications than any other breast AI vendor. It's designed to be vendor-agnostic and compatible with various acquisition gantries and reading environments. Other AI solutions for breast imaging exist, and partnerships, such as with Aidoc and Densitas, aim to integrate Transpara into broader AI platforms for a more comprehensive solution.
Specific pricing details for Transpara are not publicly available in the provided information. However, ScreenPoint Medical emphasizes seamless integration into existing clinical workflows and PACS systems. They work with IT teams to ensure smooth deployment and offer cloud-enabled access through platforms like Microsoft's Precision Imaging Network to simplify integration and scalability.
ScreenPoint Medical states that the security of their systems and the safety of patient data are paramount, with their security program aligned with ISO/IEC 27001 standards. They are committed to complying with European Data Protection Laws regarding information transferred outside the EEA and have a policy of limited access to personal data within their organization.
Yes, Transpara is cleared and marked for use with both 2D Full-Field Digital Mammography (FFDM) and 3D Digital Breast Tomosynthesis (DBT). It is designed to assist radiologists in interpreting both types of exams, providing decision support and enhancing workflow regardless of the acquisition type.

Related Tools

Stanford University
Stanford University
Clinical Decision Support & Reference
Stanford Online's "AI in Healthcare" program provides a comprehensive overview of artificial intelligence's applications and implications within the medical field.
RADIN Health
RADIN Health
Clinical Decision Support & Reference
RADINA is an AI-powered platform by RADIN Health designed to optimize radiology workflows, enhance diagnostic accuracy, and streamline reporting.
Med-PaLM 2
Google
Clinical Decision Support & Reference
Med-PaLM 2 is a large language model from Google, fine-tuned for healthcare to provide high-quality answers to medical questions and support clinical decision-making.
Pacmed Critical Discharge
Pacmed
Clinical Decision Support & Reference
Pacmed Critical Discharge is an AI tool that predicts the probability of death or readmission within seven days of ICU discharge, providing explainable insights for physicians.
AiZtech Labs
AiZtech Labs
Clinical Decision Support & Reference
AiZtech Labs provides enterprise-grade AI solutions for healthcare, focusing on operational efficiency, diagnostic accuracy, and patient care workflows for providers and health systems.
Stethophone Pro
Sparrow Acoustics
Cardiology AI
Stethophone Pro transforms smartphones into advanced cardiac screening tools, enabling clinicians to capture, interpret, and visualize heart sounds for early detection of cardiovascular diseases.

See all Clinical Decision Support & Reference tools →

More from ScreenPoint Medical

Transpara
ScreenPoint Medical
Clinical Decision Support & Reference
V. that enhances breast cancer detection and optimizes radiologist workflow for 2D and 3D mammography.
Transpara Density
ScreenPoint Medical
Oncology AI
Transpara Density is an AI-powered software that automates breast density assessment, providing BI-RADS-like and volumetric breast density (VBD) measurements for consistent and compliant reporting in mammography.

View company profile →

Suggest an Edit → | Report an issue | Last Verified: 2026-08-05 | First Added: 2026-08-05
AI Tool Finder
AI-powered search. Results may not be comprehensive.